326 related articles for article (PubMed ID: 21396529)
1. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Neuner EA; Yeh JY; Hall GS; Sekeres J; Endimiani A; Bonomo RA; Shrestha NK; Fraser TG; van Duin D
Diagn Microbiol Infect Dis; 2011 Apr; 69(4):357-62. PubMed ID: 21396529
[TBL] [Abstract][Full Text] [Related]
2. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
Menekşe Ş; Çağ Y; Işık ME; Şahin S; Hacıseyitoğlu D; Can F; Ergonul O
Int J Infect Dis; 2019 Sep; 86():208-211. PubMed ID: 31402295
[TBL] [Abstract][Full Text] [Related]
3. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
[TBL] [Abstract][Full Text] [Related]
5. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study.
Giannella M; Graziano E; Marconi L; Girometti N; Bartoletti M; Tedeschi S; Tumietto F; Cristini F; Ambretti S; Berlingeri A; Lewis RE; Viale P
Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1965-1970. PubMed ID: 28567543
[TBL] [Abstract][Full Text] [Related]
7. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality.
Capone A; Giannella M; Fortini D; Giordano A; Meledandri M; Ballardini M; Venditti M; Bordi E; Capozzi D; Balice MP; Tarasi A; Parisi G; Lappa A; Carattoli A; Petrosillo N
Clin Microbiol Infect; 2013 Jan; 19(1):E23-E30. PubMed ID: 23137235
[TBL] [Abstract][Full Text] [Related]
8. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options.
Kontopidou F; Giamarellou H; Katerelos P; Maragos A; Kioumis I; Trikka-Graphakos E; Valakis C; Maltezou HC;
Clin Microbiol Infect; 2014 Feb; 20(2):O117-23. PubMed ID: 23992130
[TBL] [Abstract][Full Text] [Related]
9. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study.
Mouloudi E; Massa E; Piperidou M; Papadopoulos S; Iosifidis E; Roilides I; Theodoridou T; Kydona C; Fouzas I; Imvrios G; Papanikolaou V; Gritsi-Gerogianni N
Transplant Proc; 2014 Nov; 46(9):3219-21. PubMed ID: 25420864
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of dual colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India.
Kaur A; Gandra S; Gupta P; Mehta Y; Laxminarayan R; Sengupta S
Am J Infect Control; 2017 Nov; 45(11):1289-1291. PubMed ID: 28807425
[TBL] [Abstract][Full Text] [Related]
11. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
[TBL] [Abstract][Full Text] [Related]
12. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Vieceli T; Henrique LR; Rech TH; Zavascki AP
J Infect Chemother; 2024 Jul; 30(7):621-625. PubMed ID: 38244722
[TBL] [Abstract][Full Text] [Related]
13. Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience.
Veeraraghavan B; Shankar C; Karunasree S; Kumari S; Ravi R; Ralph R
Pathog Glob Health; 2017 Jul; 111(5):240-246. PubMed ID: 28670975
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.
Gaibani P; Lombardo D; Lewis RE; Mercuri M; Bonora S; Landini MP; Ambretti S
J Antimicrob Chemother; 2014 Jul; 69(7):1856-65. PubMed ID: 24648503
[TBL] [Abstract][Full Text] [Related]
15. Dose-Dependent Synergistic Interactions of Colistin with Rifampin, Meropenem, and Tigecycline against Carbapenem-Resistant Klebsiella pneumoniae Biofilms.
Geladari A; Simitsopoulou M; Antachopoulos C; Roilides E
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642942
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area.
Cristina ML; Alicino C; Sartini M; Faccio V; Spagnolo AM; Bono VD; Cassola G; De Mite AM; Crisalli MP; Ottria G; Schinca E; Pinto GL; Bottaro LC; Viscoli C; Orsi A; Giacobbe DR; Icardi G;
J Infect Public Health; 2018; 11(2):171-177. PubMed ID: 28668656
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Demirlenk YM; Gücer LS; Uçku D; Tanrıöver C; Akyol M; Kalay Z; Barçın E; Akcan RE; Can F; Gönen M; Ergönül Ö
Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):761-769. PubMed ID: 35303195
[TBL] [Abstract][Full Text] [Related]
18. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae.
Falcone M; Bassetti M; Tiseo G; Giordano C; Nencini E; Russo A; Graziano E; Tagliaferri E; Leonildi A; Barnini S; Farcomeni A; Menichetti F
Crit Care; 2020 Jan; 24(1):29. PubMed ID: 32000834
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy and safety of different antimicrobial regimens in carbapenem-resistant
Sun WM; Zhou H; Shen LS; Yang Q; Ma WJ; Zhou JY
Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):566-571. PubMed ID: 31365977
[No Abstract] [Full Text] [Related]
20. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.
Petrosillo N; Giannella M; Lewis R; Viale P
Expert Rev Anti Infect Ther; 2013 Feb; 11(2):159-77. PubMed ID: 23409822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
